Contributors: Michael Mithoefer, M.D., Annie Mithoefer, B.S.N., Lisa Jerome, Ph.D., June Ruse, Psy.D., Rick Doblin, Ph.D., Elizabeth Gibson, M.S., Marcela Ot’alora G., L.P.C., Evan Sola, Psy.D. candidate
The Multidisciplinary Association for Psychedelic Studies (MAPS) is sponsoring clinical trials to explore the potential risks and benefits of 3,4-methylenedioxy-N-methylamphetamine (MDMA)-assisted therapy in chronic posttraumatic stress disorder (PTSD) participants.
This manual provides researchers with a method of MDMA-assisted therapy to be used as a model in conducting these trials. This manual is intended only for use with subjects of an approved clinical trial who have provided their informed consent.
- Download the Treatment Manual (Version 8.1: May 22, 2017)
- A Manual for Adherence Ratings of MDMA-Assisted Therapy for Treatment of Posttraumatic Stress Disorder (Version 6: August 3, 2021)
